Benign neoplasm of adrenal gland

Summary

Benign neoplasm of adrenal gland (MONDO:0021511) is a cancer with 7 GWAS associations across 7 studies. A subtype of benign endocrine neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• GWAS associations: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign neoplasm of adrenal gland
Mondo ID	MONDO:0021511
ICD-10-CM	D35.0
ICD-11	2121003176
NCIT	C3629
SNOMED CT	91967007
UMLS	C0154040
MedGen	56330
GARD	0025326
Anatomy (UBERON)	UBERON:0002369
Is cancer (heuristic)	yes

Also known as: adrenal gland benign neoplasm · benign adrenal gland neoplasm · benign adrenal gland tumor · benign adrenal gland tumour · benign adrenal neoplasm · benign adrenal tumor · benign adrenal tumour · benign neoplasm of the adrenal gland · benign tumor of adrenal gland · benign tumor of the adrenal gland · benign tumour of adrenal gland · benign tumour of the adrenal gland

Data availability: 7 GWAS associations (7 studies).

Disease family

This is a subtype of benign endocrine neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › benign endocrine neoplasm › benign neoplasm of adrenal gland

Related subtypes (13): liver lipoma, liver hemangioma, bile duct papillary neoplasm, liver leiomyoma, benign carotid body paraganglioma, benign thyroid gland neoplasm, pineocytoma, hepatocellular adenoma, benign neoplasm of pituitary gland, benign neoplasm of parathyroid gland, benign neoplasm of thymus, TMEM127-related tumor predisposition, MAX-related tumor predisposition

Subtypes (3): adrenal cortex adenoma, adrenal gland myelolipoma, benign neoplasm of adrenal medulla

Genetics & variants

GWAS landscape

7 GWAS associations across 7 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs2257089	5e-27	COX5BP8 - SOAT1	A	0.27
chr1:179273941	9e-22		G	0.29
rs193070759	4e-12	LINC02109 - LINC02064	A	2.83
rs1053076916	5e-12	TCF4	C	2.51
rs531877822	2e-11	NKAIN2	G	2.93
rs140892579	4e-11	CCDC102B - DOK6	T	2.68
rs199514012	8e-08	IQCJ-SCHIP1, IQCJ	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475631	Verma A	2024	2,605	446,602	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477290	Verma A	2024	1,058	120,172	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479854	Verma A	2024	1,058	120,172	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651805	Liu TY	2025	273	234,488	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90481560	Verma A	2024	245	59,501	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90435679	Zhou W	2018	185	407,399	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90043609	Jiang L	2021	119	456,229	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	2
low_freq (0.01-0.05)	0
rare (<0.01)	4
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	3
intron_variant	3
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs2257089	1	179289372	A>G	0.257	intergenic_variant	COX5BP8 - SOAT1	5e-27	Tier 4: intronic/intergenic
chr1:179273941				0.25			9e-22	Tier 4: intronic/intergenic
rs193070759	5	29303716	A>G	0.002	intergenic_variant	LINC02109 - LINC02064	4e-12	Tier 4: intronic/intergenic
rs1053076916	18	55451663	C>T	0	intron_variant	TCF4	5e-12	Tier 4: intronic/intergenic
rs531877822	6	124037461	G>T	0	intron_variant	NKAIN2	2e-11	Tier 4: intronic/intergenic
rs140892579	18	69344700	T>A,C	0	intergenic_variant	CCDC102B - DOK6	4e-11	Tier 4: intronic/intergenic
rs199514012	3	159169259	T>C		intron_variant	IQCJ-SCHIP1, IQCJ	8e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.